MXPA05008080A - Inhibidores peptidicos de toxinas derivadas de la ll-37. - Google Patents

Inhibidores peptidicos de toxinas derivadas de la ll-37.

Info

Publication number
MXPA05008080A
MXPA05008080A MXPA05008080A MXPA05008080A MXPA05008080A MX PA05008080 A MXPA05008080 A MX PA05008080A MX PA05008080 A MXPA05008080 A MX PA05008080A MX PA05008080 A MXPA05008080 A MX PA05008080A MX PA05008080 A MXPA05008080 A MX PA05008080A
Authority
MX
Mexico
Prior art keywords
toxins
peptide inhibitors
toxins derived
compounds
relates
Prior art date
Application number
MXPA05008080A
Other languages
English (en)
Inventor
Johannes Jakobus Grote
Original Assignee
Octoplus Technologies B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octoplus Technologies B V filed Critical Octoplus Technologies B V
Publication of MXPA05008080A publication Critical patent/MXPA05008080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a un grupo de compuestos peptidos que tienen afinidad por toxinas y especialmente por toxinas bacterianas, tales como el lipopolisacarido o el acido lipoteicoico. Estos compuestos pueden inhibir o neutralizar las toxinas. Ademas, la presente invencion se refiere al uso de estos compuestos como agentes terapeuticos o de diagnostico.
MXPA05008080A 2003-01-28 2004-01-27 Inhibidores peptidicos de toxinas derivadas de la ll-37. MXPA05008080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075274 2003-01-28
PCT/NL2004/000060 WO2004067563A1 (en) 2003-01-28 2004-01-27 Peptide inhibitors of toxins derived from ll-37

Publications (1)

Publication Number Publication Date
MXPA05008080A true MXPA05008080A (es) 2006-02-08

Family

ID=32798944

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008080A MXPA05008080A (es) 2003-01-28 2004-01-27 Inhibidores peptidicos de toxinas derivadas de la ll-37.

Country Status (20)

Country Link
US (1) US7807617B2 (es)
EP (1) EP1587830B1 (es)
JP (1) JP4471968B2 (es)
KR (1) KR100856819B1 (es)
CN (1) CN1798764B (es)
AT (1) ATE435870T1 (es)
AU (1) AU2004207118B2 (es)
BR (1) BRPI0407022A (es)
CA (1) CA2514584C (es)
CR (1) CR7926A (es)
DE (1) DE602004021901D1 (es)
DK (1) DK1587830T3 (es)
ES (1) ES2328571T3 (es)
HK (1) HK1088613A1 (es)
MX (1) MXPA05008080A (es)
NZ (1) NZ541657A (es)
PT (1) PT1587830E (es)
RU (1) RU2346950C2 (es)
WO (1) WO2004067563A1 (es)
ZA (1) ZA200506411B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
US7465784B2 (en) * 2006-10-26 2008-12-16 Board Of Regents Of The University Of Nebraska Antimicrobial peptides and methods of identifying the same
AU2008279087A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infection using same
US20130123201A1 (en) * 2010-02-25 2013-05-16 University Of Manitoba Modulation of cytokine-induced chronic inflammatory responses
WO2013078217A2 (en) 2011-11-21 2013-05-30 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and methods of use thereof
US10723764B2 (en) 2011-11-21 2020-07-28 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and methods of use thereof
BR112015005891A2 (pt) * 2012-09-17 2017-08-08 F Hoffmann La Roche Ltd método de sintetizar análogos do hormônio da tireoide e polimorfos destes
CA2963175A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
RU2584089C1 (ru) * 2015-06-15 2016-05-20 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Медицинский Университет Имени В.И. Разумовского" Министерства Здравоохранения Российской Федерации Способ снижения летального эффекта бактериального липополисахарида in vitro
CN105859867A (zh) * 2016-05-30 2016-08-17 黄石市中心医院 一种人源抗菌肽ll-37突变体及其应用
CN108892719B (zh) * 2018-07-09 2021-07-30 珠海中科先进技术研究院有限公司 一种新型人源抗菌肽ll-37衍生物及其应用
CN113116811A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 可注射长效镇痛药物组合物及其制备方法和用途
US20230080811A1 (en) * 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103888A (en) * 1992-07-17 2000-08-15 Panorama Research, Inc. Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
JP4037525B2 (ja) * 1998-03-25 2008-01-23 生化学工業株式会社 新規抗菌性ペプチド

Also Published As

Publication number Publication date
ZA200506411B (en) 2006-04-26
BRPI0407022A (pt) 2006-01-10
WO2004067563A8 (en) 2004-12-02
HK1088613A1 (en) 2006-11-10
CR7926A (es) 2006-02-07
AU2004207118B2 (en) 2009-12-17
CN1798764B (zh) 2010-05-12
DK1587830T3 (da) 2009-10-26
ES2328571T3 (es) 2009-11-16
EP1587830B1 (en) 2009-07-08
DE602004021901D1 (de) 2009-08-20
KR100856819B1 (ko) 2008-09-05
AU2004207118A1 (en) 2004-08-12
CA2514584C (en) 2012-05-29
JP4471968B2 (ja) 2010-06-02
RU2346950C2 (ru) 2009-02-20
NZ541657A (en) 2009-01-31
US20060223755A1 (en) 2006-10-05
ATE435870T1 (de) 2009-07-15
WO2004067563A1 (en) 2004-08-12
PT1587830E (pt) 2009-09-23
CA2514584A1 (en) 2004-08-12
RU2005127076A (ru) 2006-01-20
EP1587830A1 (en) 2005-10-26
CN1798764A (zh) 2006-07-05
US7807617B2 (en) 2010-10-05
JP2007528696A (ja) 2007-10-18
KR20060012261A (ko) 2006-02-07

Similar Documents

Publication Publication Date Title
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
MXPA05008080A (es) Inhibidores peptidicos de toxinas derivadas de la ll-37.
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA04000173A (es) Compuestos basados en peptidos.
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005103084A3 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
MXPA05007711A (es) Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
TW200630367A (en) Substituted adenines and the uses thereof
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
TW200503708A (en) Gyrase inhibitors and uses thereof
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
WO2006011792A3 (en) Antimicrobial peptides derived from cap18
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2007117680A3 (en) Methods and compositions for treating bacterial infection
GB0404374D0 (en) Treatment of bacterial infections
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
HK1113162A1 (en) Treatment of fungal and/or protist infections

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ACADEMISCH ZIEKENHUIS LEIDEN

FA Abandonment or withdrawal